Sandbox endocarditis: Difference between revisions

Jump to navigation Jump to search
 
(6 intermediate revisions by the same user not shown)
Line 104: Line 104:
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses'''''
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses'''''
|-
|-
|Minimum inhibitory concentration ≤ 0.12 μg/mL.
|
Minimum inhibitory concentration ≤ 0.12 μg/mL.
:† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function.
:† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function.


Line 121: Line 122:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus bovis Relatively Resistant to Penicillin (MIC >0.12 μg/mL- ≤ 0.5 μg/mL))}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus Bovis Relatively Resistant to Penicillin (MIC >0.12 μg/mL- ≤ 0.5 μg/mL))}}
|-
|-
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
Line 189: Line 190:
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''40 mg/kg per 24 h IV or in 2 or 3 equally divided doses'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''40 mg/kg per 24 h IV or in 2 or 3 equally divided doses'''''
|-
|-
|*Dosages recommended are for patients with normal renal function.
|
*Dosages recommended are for patients with normal renal function.


:† Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min.
:† Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min.
Line 202: Line 204:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin relatively or fully resistant strain (MIC >0.12 >μg/mL))}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Penicillin Relatively or Fully Resistant Strain (MIC >0.12 >μg/mL)}}
|-
|-
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
Line 235: Line 237:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml)}}
|-
|-
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
Line 261: Line 263:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen)}}
|-
|-
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>'''''
Line 340: Line 342:
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table18" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin}}
|-
|-
Line 369: Line 371:
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks'''''<br> ''PLUS'' <br> ▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks'''''
|-
|-
|*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months.
|
*Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months.
*6-wk therapy recommended for patients with symptoms >3 months.
*6-wk therapy recommended for patients with symptoms >3 months.
*Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended.
*Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended.
Line 380: Line 383:
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table19" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin}}
|-
|-
Line 423: Line 426:
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table20" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|β-Lactamase–producing strain}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|β-Lactamase–producing strain}}
|-
|-
Line 460: Line 463:
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table21" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;"
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|E faecium}}
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|E faecium}}
|-
|-

Latest revision as of 21:12, 5 March 2014

Streptococci

▸ Click on the following categories to expand treatment regimens.

Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis

  ▸  Viridans Group Streptococci and Streptococcus Bovis Highly Penicillin-Susceptible

  ▸  Viridans Group Streptococci and Streptococcus Bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL)

Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis

  ▸  Viridans Group Streptococci and Streptococcus Bovis Penicillin-Susceptible Strain (MIC ≤ 0.12 μg/mL)

  ▸  Viridans Group Streptococci and Streptococcus Bovis Penicillin Relatively or Fully Resistant Strain (MIC >0.12 μg/mL)

  ▸  Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml)

  ▸  Relatively Penicillin-Resistant Streptococci (MIC > 0.5 µg/ml)

  ▸  Unable to tolerate Penicillin or Ceftriaxone

Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis
Preferred Regimen ( 4 wks )
Adult dose
Penicillin G sodium † 12–18 million U/24 h IV either continuously or in 4-6 equally divided doses x 4 Wks
OR
Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 4 Wks
Pediatric dose ₳
Penicillin G sodium 200 000 U/kg q24h IV either continuously or in 4-6 equally divided doses x 4 Wks
OR
Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 4 Wks
Alternative Regimen ( 2 wks )
Adult dose
Penicillin G sodium‡ 12–18 million U/24 h IV either continuously or in 6 equally divided doses x 2 Wks
OR
Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 2 Wks
PLUS
Gentamicin sulfate ฿ 3 mg/Kg per 24h 1 dose x 2 Wks
Pediatric dose
Penicillin G sodium 200 000 U/kg q24h IV in 4-6 equally divided doses x 2 Wks
OR
Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 2 Wks
PLUS
Gentamicin sulfate 3 mg/Kg per 24h 1 dose or 3 equally divided doses x 2 Wks
Alternative Regimen
Adult dose
Vancomycin hydrochloride ¶ 15 mg/kg q12h IV x 4 Wks
Doses should not to exceed 2 g/24 h unless concentrations in serum are inappropriately low
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h IV in 2–3 equally divided doses

Minimum inhibitory concentration ≤ 0.12 μg/mL.

† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function.
₳ Pediatric dose should not exceed that of a normal adult.
‡ 2-wk regimen not intended for patients with known cardiac or extracardiac abscess or for those with creatinine clearance of <20 mL/min, impaired 8th cranial nerve function, or Abiotrophia, Granulicatella, or Gemella spp infection; gentamicin dosage should be adjusted to achieve peak serum concentration of 3-4 μg/mL and trough serum concentration of >1 μg/mL when 3 divided doses are used; nomogram used for single daily dosing.
¶ Vancomycin therapy recommended only for patients unable to tolerate penicillin or ceftriaxone; vancomycin dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/mL and a trough concentration range of 10–15 μg/mL
฿ Other potentially nephrotoxic drugs (eg, nonsteroidal antiinflammatory drugs) should be used with caution in patients receiving gentamicin therapy. Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.
Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus Bovis Relatively Resistant to Penicillin (MIC >0.12 μg/mL- ≤ 0.5 μg/mL))
Preferred Regimen
Adult dose
Penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose x 4 wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose x 2 wks
Pediatric dose
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
OR
Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose or equally divided doses
Alternative Regimen
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 4 wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h IV or in 2 or 3 equally divided doses
Penicillin-susceptible strain (MIC ≤ 0.12 g/mL)
Preferred Regimen
Adult dose
Penicillin G sodium † 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose x 6 wks
WITH OR WITHOUT
Gentamicin sulfate ‡ 3 mg/kg per 24 h IV/IM in 1 dose x 2 wks
Pediatric dose
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
OR
Ceftriaxone 100 mg/kg IV/IM once daily
WITH OR WITHOUT
Gentamicin 3 mg/kg per 24 h IV/IM, in 1 dose or 3 equally divided doses
Alternative Regimen
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Pediatric dose
40 mg/kg per 24 h IV or in 2 or 3 equally divided doses
  • Dosages recommended are for patients with normal renal function.
† Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min.
‡ Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.
Penicillin Relatively or Fully Resistant Strain (MIC >0.12 >μg/mL)
Preferred Regimen
Adult dose
Penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose x 6 wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose x 6 wks
Pediatric dose
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
Alternative Regimen
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h IV or in 2 or 3 equally divided doses
Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml)
Preferred Regimen
Adult dose
Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks
OR
Ceftriaxone 2 g/24 h IV/IM in 1 dose
AND
Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks
Pediatric dose
Penicillin G potassium 300 000 U/24 h IV in 4–6 equally divided doses X 4 Wks
OR
Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
AND
Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses X 2 Wks
Relatively Penicillin-Resistant Streptococci(MIC > 0.5 µg/ml, consider Enterococcal regimen)
Preferred Regimen
Adult dose
Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 Wks
PLUS
Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr x 2 Wks
Pediatric dose
Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 Wks
PLUS
Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr x 2 Wks
Unable to Tolerate Aqueous crystalline penicillin G sodium or Ceftriaxone
Preferred Regimen
Adult dose
Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h, unless serum concentrations are inappropriately low
Pediatric dose
Vancomycin 40 mg/kg 24 h in 2 or 3 equally divided doses X 4 Wks

Enterococci

Endocarditis Caused by Enterococci

  ▸  Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin

  ▸  Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin

  ▸  Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin

  ▸  Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin

Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
Preferred Regimen
Adult dose
Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks
OR
Penicillin G sodium 18–30 million U. I.V. daily in 6 equally divided doses x 4–6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 4-6 Wks
Pediatric dose
Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; X 4–6 Wks
OR
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses X 4–6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks
Alternative Regimen
Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Vancomycin 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks
  • Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months.
  • 6-wk therapy recommended for patients with symptoms >3 months.
  • Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended.
  • Vancomycin therapy recommended only for patients unable to tolerate penicillin or ampicillin.
  • 6 wk of vancomycin therapy recommended because of decreased activity against enterococci.
Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
Preferred Regimen
Adult dose
Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks
OR
Penicillin G sodium 24 million U. I.V. continuously or in 6 equally divided doses x 4–6 Wks
PLUS
Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks
Pediatric dose
Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; x 4–6 Wks
OR
Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses x 4–6 Wks
PLUS
Streptomycin sulfate 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses
Alternative Regimen
Adult dose
Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks
PLUS
Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks
Pediatric dose
Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses X 4–6 Wks
PLUS
Streptomycin sulfate 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses
  • Native valve: 4-wk therapy recommended for patients with symptoms of illness < 3 months.
  • 6-wk therapy recommended for patients with symptoms >3 months.
  • Prosthetic valve or other prosthetic cardiac material: minimum of 6 wk of therapy recommended.
  • Vancomycin therapy recommended only for patients unable to tolerate penicillin or ampicillin.
β-Lactamase–producing strain
Preferred Regimen
Adult dose
Ampicillin-sulbactam 12 g/24 h IV in 4 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Ampicillin-sulbactam 300 mg/kg per 24 h IV in 4 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Alternative Regimen
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Intrinsic penicillin resistance
Adult dose
Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses
PLUS
Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
E faecium
Adult dose
Linezolid 1200 mg/24 h IV/PO in 2 equally divided doses x ≥8 Wks
OR
Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses x ≥ 8 Wks
Pediatric dose
Linezolid 30 mg/kg per 24 h IV/PO in 3 equally divided doses ≥8 Wks
OR
Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses ≥8 Wks
E faecalis
Adult dose
Preferred Regimen
Imipenem/cilastatin 2 g/24 h IV in 4 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks
Pediatric dose
Imipenem/cilastatin 60–100 mg/kg per 24 h IV in 4 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 300 mg/kg per 24

h IV in 4–6 equally divided doses x ≥ 8 Wks

Alternative Regimen
Adult dose
Ceftriaxone sodium 4 g/24 h IV/IM in 2 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks
Pediatric dose
Ceftriaxone sodium 100 mg/kg per 24 h IV/IM in 2 equally divided doses x ≥8 Wks
PLUS
Ampicillin sodium 300 mg/kg per 24 h IV in 4–6 equally divided doses x ≥ 8 Wks
  • Patients with endocarditis caused by these strains should be treated in consultation with an infectious diseases specialist.
  • Cardiac valve replacement may be necessary for bacteriologic cure.
  • Cure with antimicrobial therapy alone may be < 50%
  • Severe, usually reversible thrombocytopenia may occur with use of linezolid, especially after 2 wk of therapy.
  • Quinupristin-dalfopristin only effective against E faecium and can cause severe myalgias, which may require discontinuation of therapy
  • Only small no. of patients have reportedly been treated with imipenem/cilastatin-ampicillin or ceftriaxone + ampicillin.

Staphylococci

Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material

  ▸  Staphylococci (Methicillin Susceptible)

  ▸  Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity

Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci

  ▸  Oxacillin-Susceptible Strains

  ▸  Oxacillin-Resistant Strains

Staphylococci (Methicillin Susceptible)
Preferred Regimen
Adult dose
Nafcillin or Oxacillin † 12 g I.V. daily in equally divided doses x 6 Wks
PLUS (optional)
Gentamicin sulfate ‡ 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days
Altenative Regimen( in non anaphylactoid Penicillin hypersensitivity)
Cefazolin 6 g/ 24 h I.V. in 3 divided doses x 6 wks
PLUS (optional)
Gentamicin 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days
Pediatrics dose
Nafcillin or oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses x 4-6 wks
OR ( in non anaphylactoid Penicillin hypersensitivity)
Cefazolin 100 mg/kg per 24 h IV in 3 equally divided doses x 4-6 wks
AND (optional)
Gentamicin 3 mg/kg per 24 h IV/IM in 3 equally divided doses
† Penicillin G 24 million U/24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin susceptible (MIC ≤ 0.1 μg/mL) and does not produce β-lactamase.
‡ Gentamicin should be administered in close temporal proximity to vancomycin, nafcillin, or oxacillin dosing.
Staphylococci (Methicillin-resistant)
(in anaphylactoid Penicillin hypersensitivity)
Preferred Regimen
Adult dose
Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Adjust vancomycin dosage to achieve 1-h serum concentration of 30–45 > g/mL and trough concentration of 10–15 >g/mL
Pediatrics dose
Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses x 6 wks
Oxacillin-susceptible strains
Adult dose
Nafcillin or oxacillin 2 g q4h IV x ≥6 weeks
PLUS
Rifampin 300 mg q8h IV/PO x ≥6 weeks
PLUS
Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 weeks
Pediatric dose
Nafcillin or oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses
PLUS
Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses
PLUS
Gentamicin 1 mg/kg q8h IV/IM
Oxacillin-resistant strains
Adult dose
Vancomycin 15 mg/kg q12h x ≥6 Wks
PLUS
Rifampin 300 mg q8h IV/PO x ≥6 Wks
PLUS
Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 wks
Pediatric dose
Vancomycin 40 mg/kg per 24 h IV in 2-3 equally divided doses x ≥6 wks
PLUS
Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses x ≥6 wks
PLUS
Gentamicin 1 mg/kg q8h IV/IM x 2 Wks

HACEK Organisms

HACEK organisms are more indolent and the infection is less complicated. [1]

  ▸  Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms

Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms
Adult dose
Ceftriaxone sodium † 2 g/24 h IV/IM in 1 dose x 4 weeks
OR
Ampicillin- sulbactam ‡ 12 g/24 h IV in 4 equally divided doses x 4 weeks
OR
Ciprofloxacin ‡¶ 500 mg q12h PO or 400 mg q12h IV x 4 weeks
Pediatric dose
Ceftriaxone 100 mg/kg per 24 h IV/IM once daily
OR
Ampicillin- sulbactam 300 mg/kg per 24 h IV divided into 4 or 6 equally divided doses
OR
Ciprofloxacin 10-15 mg/kg q12h IV/PO
  • HACEK: Haemophilus parainfluenzae, H aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.
† Patients should be informed that IM injection of ceftriaxone is painful.
‡ Dosage recommended for patients with normal renal function.
¶ Fluoroquinolones are highly active in vitro against HACEK microorganisms. Published data on use of fluoroquinolone therapy for endocarditis caused by HACEK are minimal.
  1. Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter |month= ignored (help)